Friedrich-Alexander Ludwig

List of Publications by Year
in descending order

28 papers	252 citations	1039406 9 h-index	996533 15 g-index
28 all docs	28 docs citations	28 times ranked	383 citing authors

#	Article	IF	Citations
1	Role of TRPC6 in kidney damage after acute ischemic kidney injury. Scientific Reports, 2022, 12, 3038.	1.6	7
2	Development and Biological Evaluation of the First Highly Potent and Specific Benzamide-Based Radiotracer [18F]BA3 for Imaging of Histone Deacetylases 1 and 2 in Brain. Pharmaceuticals, 2022, 15, 324.	1.7	0
3	A Pharmacokinetic and Metabolism Study of the TRPC6 Inhibitor SH045 in Mice by LC-MS/MS. International Journal of Molecular Sciences, 2022, 23, 3635.	1.8	0
4	(+)-[18F]Flubatine as a novel Î±4Î²2 nicotinic acetylcholine receptor PET ligandâ€"results of the first-in-human brain imaging application in patients with Î²-amyloid PET-confirmed Alzheimerâ€™s disease and healthy controls. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 731-746.	3.3	10
5	Development of 18F-Labeled Radiotracers for PET Imaging of the Adenosine A2A Receptor: Synthesis, Radiolabeling and Preliminary Biological Evaluation. International Journal of Molecular Sciences, 2021, 22, 2285.	1.8	5
6	Preclinical Evaluation of [18F]FACH in Healthy Mice and Piglets: An 18F-Labeled Ligand for Imaging of Monocarboxylate Transporters with PET. International Journal of Molecular Sciences, 2021, 22, 1645.	1.8	0
7	Improved in vivo PET imaging of the adenosine A2A receptor in the brain using [18F]FLUDA, a deuterated radiotracer with high metabolic stability. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2727-2736.	3.3	18
8	Validation of an LC-MS/MS Method to Quantify the New TRPC6 Inhibitor SH045 (Larixyl) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 Td (N Pharmaceuticals, 2021, 14, 259.	1.7	3
9	Design, Radiosynthesis and Preliminary Biological Evaluation in Mice of a Brain-Penetrant 18F-Labelled Ïƒ2 Receptor Ligand. International Journal of Molecular Sciences, 2021, 22, 5447.	1.8	6
10	Development of fluorinated and methoxylated benzothiazole derivatives as highly potent and selective cannabinoid CB2 receptor ligands. Bioorganic Chemistry, 2021, 114, 105191.	2.0	4
11	Development of Novel Analogs of the Monocarboxylate Transporter Ligand FACH and Biological Validation of One Potential Radiotracer for Positron Emission Tomography (PET) Imaging. Molecules, 2020, 25, 2309.	1.7	4
12	Sigma-1 Receptor Positron Emission Tomography: A New Molecular Imaging Approach Using (S)-(â^')-[18F]Fluspidine in Glioblastoma. Molecules, 2020, 25, 2170.	1.7	5
13	Preclinical Incorporation Dosimetry of [18F]FACHâ€"A Novel 18F-Labeled MCT1/MCT4 Lactate Transporter Inhibitor for Imaging Cancer Metabolism with PET. Molecules, 2020, 25, 2024.	1.7	3
14	In vitro and in vivo Human Metabolism of (S)-[18F]Fluspidine â€" A Radioligand for Imaging Ïƒ1 Receptors With Positron Emission Tomography (PET). Frontiers in Pharmacology, 2019, 10, 534.	1.6	9
15	Synthesis and In Vitro Evaluation of 8-Pyridinyl-Substituted Benzo[e]imidazo[2,1-c][1,2,4]triazines as Phosphodiesterase 2A Inhibitors. Molecules, 2019, 24, 2791.	1.7	9
16	Targeting cyclic nucleotide phosphodiesterase 5 (PDE5) in brain: Toward the development of a PET radioligand labeled with fluorine-18. Bioorganic Chemistry, 2019, 86, 346-362.	2.0	14
17	Structureâ€"Affinity Relationships of Fluorinated Spirocyclic Ïƒ 2 Receptor Ligands with an Exocyclic Benzylamino Moiety. ChemMedChem, 2019, 14, 1392-1402.	1.6	1
18	Development and radiosynthesis of the first ¹⁸Fâ€labeled inhibitor of monocarboxylate transporters (MCTs). Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 411-424.	0.5	6

#	Article	IF	Citations
19	Radiosynthesis and Biological Investigation of a Novel Fluorine-18 Labeled Benzoimidazotriazine-Based Radioligand for the Imaging of Phosphodiesterase 2A with Positron Emission Tomography. Molecules, 2019, 24, 4149.	1.7	5
20	N^{Îµ}-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structureâ€“Activity Relationships, and Pharmacokinetic Profiling. Journal of Medicinal Chemistry, 2018, 61, 4528-4560.	2.9	27
21	Exploring the Metabolism of (+)-[18F]Flubatine In Vitro and In Vivo: LC-MS/MS Aided Identification of Radiometabolites in a Clinical PET Study â€. Molecules, 2018, 23, 464.	1.7	9
22	Radiosynthesis of (S)-[18 F] T1 : The first PET radioligand for molecular imaging of Î±3Î²4 nicotinic acetylcholine receptors. Applied Radiation and Isotopes, 2017, 124, 106-113.	0.7	6
23	LC-MS Supported Studies on the in Vitro Metabolism of both Enantiomers of Flubatine and the in Vivo Metabolism of (+)-[18F]Flubatineâ€"A Positron Emission Tomography Radioligand for Imaging Î±4Î²2 Nicotinic Acetylcholine Receptors. Molecules, 2016, 21, 1200.	1.7	12
24	Development of a New Radiofluorinated Quinoline Analog for PET Imaging of Phosphodiesterase 5 (PDE5) in Brain. Pharmaceuticals, 2016, 9, 22.	1.7	15
25	Comparison of inâ€…Silico, Electrochemical, inâ€…Vitro and inâ€…Vivo Metabolism of a Homologous Series of (Radio)fluorinated Ïƒ₁ Receptor Ligands Designed for Positron Emission Tomography. ChemMedChem, 2016, 11, 2445-2458.	1.6	12
26	Development of a Novel Nonpeptidic ¹⁸F-Labeled Radiotracer for in Vivo Imaging of Oxytocin Receptors with Positron Emission Tomography. Journal of Medicinal Chemistry, 2016, 59, 1800-1817.	2.9	17
27	Asymmetric Synthesis of Spirocyclic 2-Benzopyrans for Positron Emission Tomography of Ïƒ1 Receptors in the Brain. Pharmaceuticals, 2014, 7, 78-112.	1.7	2
28	Synthesis of Natural Product Precursors by Baeyer-Villiger Oxidation with Cyclohexanone Monooxygenase from Acinetobacter. Synthesis, 2001, 2001, 0947-0951.	1.2	43